ASO Author Reflections: Potential Values of Peritoneal Cell-Free Tumor DNA Testing

2020 ◽  
Vol 27 (13) ◽  
pp. 5072-5073
Author(s):  
Carlos H. F. Chan
Keyword(s):  
Peritoneal Cell ◽  
Dna Testing ◽  
Tumor Dna

scholarly journals Universal genetic assessment for women with ovarian cancer not yet achieved: the promises of universal tumor DNA testing

2021 ◽  
pp. 100825
Author(s):  
Vera M. Witjes ◽  
Janet R. Vos ◽  
Marjolijn J.L. Ligtenberg ◽  
Nicoline Hoogerbrugge
Keyword(s):  
Ovarian Cancer ◽  
Dna Testing ◽  
Genetic Assessment ◽  
Tumor Dna

Peritoneal Cell-Free Tumor DNA as Biomarker for Peritoneal Surface Malignancies

2020 ◽  
Vol 27 (13) ◽  
pp. 5065-5071 ◽  
Author(s):  
Katie M. Leick ◽  
Austin G. Kazarian ◽  
Maheen Rajput ◽  
Ann Tomanek-Chalkley ◽  
Ann Miller ◽  
...  
Keyword(s):  
Peritoneal Cell ◽  
Peritoneal Surface ◽  
Peritoneal Surface Malignancies ◽  
Tumor Dna

scholarly journals Feasibility and clinical value of circulating tumor DNA testing in patients with gastric adenocarcinomas

2019 ◽  
Vol 10 (3) ◽  
pp. 400-406 ◽  
Author(s):  
Madiha Iqbal ◽  
Ali Roberts ◽  
Jason Starr ◽  
Kabir Mody ◽  
Pashtoon Murtaza Kasi
Keyword(s):  
Circulating Tumor Dna ◽  
Dna Testing ◽  
Clinical Value ◽  
Gastric Adenocarcinomas ◽  
Tumor Dna

Identification of putative germline mutations in 10,288 patients undergoing circulating tumor DNA testing.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 1514-1514 ◽  
Author(s):  
Thomas Paul Slavin ◽  
Kimberly Banks ◽  
Darya Chudova ◽  
Geoffrey R. Oxnard ◽  
Justin I. Odegaard ◽  
...  
Keyword(s):  
Point Mutations ◽  
Read Depth ◽  
Circulating Tumor Dna ◽  
Tumor Burden ◽  
Hereditary Cancer Syndrome ◽  
Dna Testing ◽  
Sequencing Data ◽  
Advanced Cancer Patients ◽  
Cancer Syndrome ◽  
Tumor Dna

1514 Background: No studies have yet described incidental detection of germline cancer predisposition mutations using circulating cell-free DNA (cfDNA). Methods: Deidentified cfDNA sequencing data from 10288 advanced cancer patients (pts) undergoing clinical circulating tumor DNA testing (Guardant360, 73 genes) were included in this study. CfDNA was extracted from plasma and quantified. A DNA library was prepared and sequenced to 15,000X average read depth. Using Ingenuity Variant Analysis, point mutations and small indels suspicious for germline origin (allele fraction 40-60%) were classified following American College of Medical Genetics and Genomics guidelines. Results: More than 50 cancer types were studied, including lung (40%), breast (20%), CRC (8%), prostate (6%), and pancreas (3%). Average age was 63.6 years (range:18-95), 42% were male. Of 34,873 putative germline variants identified, 520 (1.5%) were pathogenic or likely pathogenic (PV), 16,939 (49%) were of uncertain significance, and 17,414 (50%) were benign or likely benign. Of the 250 pts (2.4%) with hereditary cancer syndrome gene PVs, 83 were excluded due to high level of somatic tumor burden leaving 167 (1.6%) with putative germline PVs; rates were higher in pts <50 vs >50 overall (3.3% vs 1.4%, p=0.02) and in breast cancer pts (4.3% vs 1.5%, p=0.03). Conclusions: The observed frequency of incidentally identified putative germline PVs is expectedly lower than the true germline rate; however, these findings illustrate that detection from cfDNA is clinically feasible. Importantly, incidental germline findings could impact oncology treatment planning (e.g. PARP inhibitors for BRCA1/2 mutations) and could benefit families via increased surveillance/primary prevention. Further research is needed to explore how to report potential germline results to clinicians using a systems-based approach. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document